Repligen Reports First Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Repligen Reports First Quarter 2025 Financial Results
April 29, 2025 4:03 PM EDT
Truist Securities analyst Srikripa Devarakonda lowered the price target on Repligen (NASDAQ: RGEN) to $940.00 (from $975.00) while maintaining a Buy rating.
The analyst comments "While near-term investor focus remains on the Eylea tail, REGN continues to deliver growth on top/bottom line... More
April 29, 2025 3:58 PM EDT
Jefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $914.00 (from $936.00) while maintaining a Buy rating.
The analyst comments "Bottom line: REGN entered Q1 w/ a fairly negative bias into the print given: 1) we were modeling Eylea to miss HERE given the issues w/ Good Days, its pt assistance... More
April 29, 2025 2:54 PM EDT
JPMorgan analyst Rachel Vatnsdal lowered the price target on Repligen (NASDAQ: RGEN) to $190.00 (from $200.00) while maintaining a Overweight rating.
The analyst comments "Repligen (RGEN) reported a strong top-line and bottom-line 1Q beat while reiterating organic revenue growth for the year. Diving deeper, RGEN revenues of $169M came in above the Street of $164M, reflecting +11% organic growth y/y (vs. Street of +7.9% y/y), leading to adj. EPS of $0.39 (vs. Street of $0.34). RGEN raised its... More
